Novasep Acquisition by its Management and by Gilde, Banexi, BNP Paribas has Been Signed
Groupe Novasep has been acquired for an enterprise value ofEUR 425 million by its management and by a financial investor group composedof Gilde Buy Out, Banexi Capital Partenaires, BNP Paribas. The acquisitionhas been signed on November 29th, 2006 and completed on January 9th 2007.
Groupe Novasep has been acquired for an enterprise value ofEUR 425 million by its management and by a financial investor group composedof Gilde Buy Out, Banexi Capital Partenaires, BNP Paribas. The acquisitionhas been signed on November 29th, 2006 and completed on January 9th 2007.
Groupe Novasep will continue to operate through two complementarydivisions contributing to approximately EUR 280 million of sales. NovasepSynthesis offers custom synthesis services utilising niche technologies toproduce elaborate molecules for the pharmaceutical industry, as well asproducing and marketing proprietary products, typically generics.Novasep Process is a recognised leader in the field of chromatography, withparticular strength in continuous processes. It provides turn-key physicalpurification solutions to industrial biotech, pharmaceutical and the growingbio-pharma industries. Headquartered in Pompey (France), Novasep operatesmainly in Europe, with subsidiaries in the United States, China and Japan and1300 employees working in nine sites.
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
LC/MS Based Characterization Workflow of GLP-1 Therapeutic Peptide Liraglutide and Its Impurities
January 14th 2025This application note demonstrates a liquid chromatography/quadrupole time-of-flight mass spectrometer (LC/Q-TOF MS) workflow for the identification and characterization of therapeutic peptides.
